Cover Image
市場調查報告書

胰臟癌:全球臨床實驗趨勢

Pancreatic Cancer Global Clinical Trials Review, H1, 2016

出版商 GlobalData 商品編碼 228234
出版日期 內容資訊 英文 1681 Pages
訂單完成後即時交付
價格
Back to Top
胰臟癌:全球臨床實驗趨勢 Pancreatic Cancer Global Clinical Trials Review, H1, 2016
出版日期: 2016年05月31日 內容資訊: 英文 1681 Pages
簡介

本報告提供全球胰臟癌治療藥臨床實驗上之相關調查,提供您各地區的臨床實驗數資料,實驗階段,實驗狀況,採用主題及各種贊助企業臨床實驗資料,臨床實驗主要的參與企業,有潛力的藥劑,最新臨床實驗相關新聞等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要5國的臨床實驗數量
    • 中南美主要5國的臨床實驗數量

G7各國臨床實驗數量:癌症治療藥臨床實驗上胰臟癌的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:癌症治療藥臨床實驗上胰臟癌的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

胰臟癌治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3415CTIDB

GlobalData's clinical trial report, "Pancreatic Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Pancreatic Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Pancreatic Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Pancreatic Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Pancreatic Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Pancreatic Cancer Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Pancreatic Cancer
      • May 18, 2016: Lilly to present data on TGFß small-molecule kinase inhibitor galunisertib at ASCO
      • May 10, 2016: First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics
      • May 09, 2016: NewLink Genetics Announces Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer
      • May 05, 2016: PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
      • Apr 27, 2016: BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer
      • Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016
      • Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 2016
      • Apr 20, 2016: OncoMed Presents Biomarker Research for Vantictumab at the AACR Annual Meeting 2016
      • Apr 19, 2016: New class of small molecule drug, SI-2, has potential for improving cancer treatment
      • Apr 18, 2016: Halozyme Expands Oncology Pipeline With PEG-ADA2 Compound Designed For Activity In The Tumor Microenvironment
      • Apr 18, 2016: BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting
      • Apr 14, 2016: Asana BioSciences, to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting
      • Apr 13, 2016: Celprogen provides an update on cancer compound CEP1430
      • Apr 13, 2016: Celprogen provides an update on cancer compound CEP1507
      • Apr 06, 2016: PharmaCyte Biotech's CEO Explains How New Clinical Trial Design Changed the GMP Certification Process
      • Apr 05, 2016: Silence Therapeutics: Atu027 update
      • Apr 05, 2016: CHK1 inhibitor CCT245737 Approved for Clinical Trials in Cancer Patients
      • Mar 31, 2016: PharmaCyte Biotech Finalizes Design of Pancreatic Cancer Clinical Trial and Identifies Trial Sites under Consideration
      • Mar 30, 2016: Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology
      • Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting
      • Mar 22, 2016: CytRx to Present New Data Using Its Proprietary LADR Technology at the 2016 American Association for Cancer Research Annual Meeting
      • Mar 21, 2016: MabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of Pancreatic Cancer
      • Mar 17, 2016: GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016
      • Mar 17, 2016: Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016
      • Mar 07, 2016: Data from MacroGenics' Preclinical Studies of MGD009 Presented at Keystone Symposia's Antibodies as Drugs (X2) Conference
      • Mar 02, 2016: Propanc Confirms PRP Response to Broad Range of Cancer Indications; Sets Date for Scientific Advice Meeting with UK Regulators
      • Feb 24, 2016: PharmaCyte Biotech on Schedule for 2016 Cancer Clinical Trial in Pancreatic Cancer
      • Feb 22, 2016: PharmaCyte Biotech Issues Update on Preparations for Its Pancreatic Cancer Clinical Trial
      • Feb 22, 2016: OncoQR ML Pancreatic Cancer Vaccine TYG100 Induces Clinically Relevant Immune Response Within Just 2 Weeks After Single Vaccination
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Pancreatic Cancer Therapeutics, Global, Clinical Trials by Region, 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Pancreatic Cancer to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Pancreatic Cancer to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Pancreatic Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Pancreatic Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Pancreatic Cancer to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Pancreatic Cancer to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Pancreatic Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Pancreatic Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Pancreatic Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top